Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine

Pain Practice

Volumn 9, Issue 2, 2009, Pages 105-114

  Aurilio, Caterina ^a   Pace, Maria Caterina ^a   Passavanti, Maria Beatrice ^a   Paladini, Antonella ^b   Maisto, Massimo ^a   Iannotti, Mario ^a   Pota, Vincenzo ^a   D'amora, Eleonora ^a   Sansone, Pasquale ^a   Barbarisi, Manlio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Buprenorphine; Epidural analgesia; Peripheral vascular disease; Transdermal opioid

Indexed keywords

BUPRENORPHINE; MORPHINE; PLACEBO; ROPIVACAINE;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MEDICAL RECORD; NAUSEA; PAIN ASSESSMENT; PATIENT SATISFACTION; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP TIME; SOMNOLENCE; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; AGED; AMIDES; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANESTHETICS, LOCAL; BUPRENORPHINE; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHINE; PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS;

EID: 61549135053     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00237.x     Document Type: Article

References (20)

1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Havrison-Principi di Medicina Interna. Milano: McGraw Hill ; 2007.
2. Sorge J, Werry C, Pichlmayr I. Strong opioids for treatment of chronic pain: A meta-analysis. Schmerz. 1997; 11: 400-410.
3. Lasalle Fontaine C, Habrant P. Symptomatic analgesic treatments of the chronic pain of obliterating arteriopathy. Cah Anesthesiol. 1990; 38: 95-99.
4. Koppert W, Ihmsen H, Korber N, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005; 118: 15-22.
5. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003; 63: 1999-2010 ; discussion 2011-2012.
6. Likar R, Griessinger N, Sadjak A, Sittl R. Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain. Wien Med Wochenschr. 2003; 153: 317-322.
7. Ben-Abraham R, Beltrutti D, Niv D, Weinbroum A. The benefit of combining spinal morphine and intravenous buprenorphine for perioperative pain. Harefuah. 2001; 140: 709-712, 806.
8. Chen LH, Nemirovsky A, Gong QY. Interaction of combined administration of intrathecal morphine with subcutaneous morphine or buprenorphine. Acta Pharmacol Sin. 2000; 21: 685-689.
9. Varrassi G. Quale dolore cronico non oncologico da trattare con Buprenorfina: Razionale. Minerva Anestesiol. 2003; 69 (suppl 1): 13-16.
10. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS: The clinical development rationale and results. Int J Clin Pract Suppl. 2003; 133: 15-18. discussion 23-4. Review.
11. Budd K. Buprenorphine and the transdermal system: The ideal match in pain management. Int J Clin Pract Suppl. 2003; 133: 9-14. discussion 23-4. Review.
12. Linderoth B, Foreman R. Physiology of spinal cord stimulation: Review and update neuromodulation. J Int Neuromodulation Soc. 1992; 3: 150-152.
13. Kenneth M. Multiple program spinal cord stimulation in the treatment of chronic pain: Follow up of multiple program SCS. Neuromodulation. 1999; 2: 266-274.
14. Luise A. La stimolazione elettrica midollare nelle malattie vascolari periferiche: Nostra esperienza. Atti 54 Congresso Nazionale SIAARTI. 2000; 85: 25-28.
15. Stock C, Shum JH. Buprenorphine: A new pharmacotherapy for opioid addictions treatment. J Pain Palliat Care Pharmacother. 2004; 18: 35-54.
16. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes Hyperalgesia during the withdrawal. Pain. 2003; 106: 1-2 ; 49-57.
17. Vanderah TW, Laughlin T, Lashbrook JM, et al. Single interthecal injenctions of dinorphin A or des-tyr-dynorphin produce long-lasting allodynia in rats: Blockade by mk-801 but not Naloxone. Pain. 1996; 68: 275-281.
18. Nemirovsky A, Chen L, Zelman V, Jurna I. The antinociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine. Anesth Analg. 2001; 93: 197-203.
19. Chelminski PR, Ives TJ, Felix KM, et al. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res. 2005; 13 ; 5: 3.
20. Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol. 2004; 19 (suppl 1): S3-7.